Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israël, Tel Aviv
Ronit El Hasid
38 années d'expérience
La clinique est certifiée :
| Israël | Turquie | Espagne | |
| Traitement complexe du neuroblastome | de $144,000 | de $28,000 | de $70,000 |
Plus de 300 transplantations oncologiques pédiatriques réalisées – Ronit El Hasid travaille exclusivement avec des enfants au centre médical Sourasky (Ichilov).
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Prof. Zvi Cohen is Director of the Neurosurgery Department and the Neuro-Oncology Unit at Sheba Medical Center. He is a neurosurgeon and neuro-oncology expert. He was included in Forbes Israel’s Best Doctors 2025. He leads clinical research on drug therapies for malignant brain tumors. He also founded Sheba’s brain tumor tissue bank.
He is board-certified in neurosurgery. He trained at Tel Aviv University. He completed fellowships in neuroradiology at Beth Israel and in neurosurgical oncology at MD Anderson. His practice covers complex brain, pituitary, spine, and spinal cord tumors. He has expertise in stereotactic biopsies, image-guided resections, intraoperative MRI, navigation systems, and radiosurgery. He is a member of the Society for Neuro-Oncology and the Israeli Association of Neurological Surgeons.
Israeli medical centers report survival rates reaching 85% for high-risk neuroblastoma patients. Specialized oncology facilities achieve a 90% success rate for general pediatric oncology cases. These outcomes stem from intensive multimodality protocols. Centers integrate advanced immunotherapy and MIBG radiation therapy for precise tumor targeting.
Bookimed Expert Insight: While survival rates are high across Israel, the logistical density at centers like Sheba is unique. Their neuroblastoma bone marrow transplant package includes a 30-day hospital stay. This extended inpatient period is significantly longer than many international protocols. It ensures maximum safety during the critical post-transplant recovery phase.
Patient Consensus: Parents often highlight the speed of diagnosis and the reassuring precision of nuclear medicine tools like MIBG. They note that having access to world-renowned specialists like Dr. Hana Golan provides immense confidence during complex treatments.
Major Israeli hospitals treating neuroblastoma include Sheba Medical Center, Sourasky (Ichilov), Hadassah, Rambam, and Schneider Children's. These facilities hold Joint Commission International (JCI) accreditation. Leading specialists include Dr. Hana Golan and Prof. Ronit El Hasid, who follow international high-risk protocols and utilize bone marrow transplantation.
Bookimed Expert Insight: Israeli medical centers demonstrate a significant scale of care, with Sheba Medical Center alone treating over 2 million patients annually. Our data shows that top-tier packages, such as those at Sheba, priced around $160,000 for complex bone marrow transplants, often include 30 hospital days. This extensive inpatient stay is a key differentiator compared to clinics in other regions that may offer shorter initial monitoring periods.
Patient Consensus: Parents emphasize the importance of contacting international coordinators early to manage visas and translations. Families note that while surgical success is high, navigating language barriers is easier when using the dedicated international wings of major centers like Sourasky.
MIBG therapy (131I-MIBG) is available in Israel at major tertiary centers like Sheba Medical Center and Rambam Health Care Campus. Facilities manage radiation safety through lead-lined isolation rooms. Specialized protocols include thyroid protection using potassium iodide. Strict monitoring ensures radioactivity stays within safe limits before patient discharge.
Bookimed Expert Insight: Israeli oncology centers often integrate MIBG therapy into comprehensive high-risk neuroblastoma protocols. At Sheba Medical Center, for example, Dr. Hana Golan serves as a lead investigator for high-risk ESIOP protocols. This high-level clinical integration means patients receive targeted molecular therapy while staying within standardized European treatment frameworks. Such coordination simplifies the transition between MIBG and other complex phases like bone marrow transplantation.
Patient Consensus: Parents find the separation during the 5–7 day isolation period emotionally difficult but understand the safety need. Patients suggest packing disposable entertainment items and using salivary protectors to manage the physical effects of radiation.
High-risk neuroblastoma treatment in Israel typically spans 15 to 18 months. Patients undergo intensive induction, consolidation, and maintenance phases. Specialized centers like Sheba Medical Center usually complete diagnostics in 3 to 5 days. Treatment involves chemotherapy, surgical resection, and autologous stem cell transplantation.
Bookimed Expert Insight: Israeli protocols often integrate autologous stem cell transplantation and immunotherapy into a single consolidated timeline. While a standard hospital stay for transplant is 30 days, centers like Sheba Medical Center manage over 2 million patients annually. Their high volume allows for rapid transitions from intensive inpatient care to daily outpatient monitoring.
Patient Consensus: Families emphasize planning for at least 12 to 18 months in Israel to account for recovery buffers. They recommend bringing comfort items for the child as isolation periods during transplant can be extended.
Israel provides comprehensive support for international families. JCI-accredited centers like Sheba and Sourasky employ English-speaking medical teams. Multidisciplinary care includes personalized nutrition and 24-hour nursing. Families receive dedicated assistance with airport-to-clinic transfers. On-site coordinators bridge language gaps throughout the neuroblastoma treatment journey.
Bookimed Expert Insight: While many think of medical care only, Sheba Medical Center bundles include 30 hospital nights. This provides a stable base for families. Coordination often starts before arrival with English-language consultations. Choosing clinics ranked by Newsweek ensures international standards for linguistic and medical support. This structure reduces the logistical burden on parents significantly.
Patient Consensus: Parents find having a dedicated coordinator essential for navigating daily hospital life. They often emphasize that having someone to translate medical details into plain English makes complex procedures feel much more manageable.
Israel actively conducts clinical trials for foreign children with relapsed or refractory neuroblastoma. Leading centers like Sheba Medical Center and Schneider Children’s participate in global research consortiums. These trials often grant international patients access to experimental immunotherapies. This including CAR T-cell therapy and novel drug protocols.
Bookimed Expert Insight: Israeli oncology centers serve over 1.8 million patients annually and maintain a 90% oncology success rate. Our data shows Sheba Medical Center is ranked in the top 10 globally by Newsweek. Dr. Hana Golan personally leads international neuroblastoma protocols at this JCI-accredited facility. This combination of global ranking and leadership ensures high-risk patients receive verified expert care.
Patient Consensus: Parents emphasize that starting the medical review early is vital for trial eligibility. They note having a dedicated case manager helps manage the complex logistics of international treatment.
Children can usually fly 1 to 2 weeks after chemotherapy or minor surgery. Stem cell transplants require longer stays. Flights are safe once blood counts stabilize and doctors confirm medical readiness for travel. Patients must carry a formal discharge letter and detailed medication list.
Bookimed Expert Insight: Israeli protocols often include MIBG therapy or CAR-T cell trials for high-risk neuroblastoma. These advanced treatments require specific monitoring periods before departure. At Sheba Medical Center, Dr. Hana Golan oversees these complex international protocols. We see that many families choose Sheba because it ranks among the top 10 hospitals globally.
Patient Consensus: Parents emphasize the importance of requesting a flight-ready letter for the airline. They also suggest booking flexible tickets in case blood counts take longer to recover.